贝伐珠单抗联合替氟尿苷/胸苷磷酸化酶抑制剂可改善转移性结直肠癌患者一线治疗中无论是否使用过贝伐珠单抗的生存结局。
Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer.
机构信息
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
出版信息
Anticancer Res. 2020 Jul;40(7):4157-4163. doi: 10.21873/anticanres.14415.
BACKGROUND/AIM: The efficacy of trifluridine/thymidine phosphorylase inhibitor (FTD/TPI) plus bevacizumab as later-line treatment for metastatic colorectal cancer (mCRC) has been demonstrated. However, little is known about the impact of a usage history of bevacizumab in front-line treatment on the clinical benefit of combining bevacizumab with FTD/TPI.
PATIENTS AND METHODS
A total of 62 patients with mCRC treated with FTD/TPI±bevacizumab was enrolled and assessed for chemotherapeutic efficacy and adverse events.
RESULTS
Regardless of the usage history of bevacizumab in front-line treatment, the FTD/TPI plus bevacizumab group had a significantly better progression-free survival rate than the FTD/TPI monotherapy group, and no significant differences in the safety profile were observed between the two groups.
CONCLUSION
Combining bevacizumab with FTD/TPI improves the survival outcomes with manageable toxicity, regardless of the usage history of bevacizumab in front-line treatment, in patients with mCRC.
背景/目的：已证实三氟胸苷/胸苷磷酸化酶抑制剂（FTD/TPI）联合贝伐珠单抗作为转移性结直肠癌（mCRC）的二线治疗具有疗效。然而，关于贝伐珠单抗在一线治疗中的使用史对贝伐珠单抗联合 FTD/TPI 联合治疗的临床获益的影响知之甚少。
患者与方法
共纳入 62 例接受 FTD/TPI±贝伐珠单抗治疗的 mCRC 患者，评估其化疗疗效和不良事件。
结果
无论贝伐珠单抗在一线治疗中的使用史如何，FTD/TPI 联合贝伐珠单抗组的无进展生存率均显著优于 FTD/TPI 单药组，且两组的安全性特征无显著差异。
结论
在 mCRC 患者中，无论贝伐珠单抗在一线治疗中的使用史如何，联合贝伐珠单抗均可改善生存结局，且毒性可耐受。
Zotero 插件